| HERZLIYA, Israel, March 29, 2012 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY), a biopharmaceutical development company, today reported its results for the fourth quarter and year ended December 31, 2011. David Grossman, CEO of XTL, stated, "2011 was a very significant year for XTL and we are very proud of our achievements in expanding our drug development pipeline with SAM-101 for the treatment of schizophrenia. SAM-101 is combination therapy of anti-psychotic existing drug...continued XTLBY |
Thursday, March 29, 2012
XTL Biopharmaceuticals Reports Full-Year 2011 Results
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment